BioAtla
BioAtla, based in San Diego, California, develops novel therapeutics for cancer treatment using its proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. The company operates in both the United States and China, holding over 700 patents and patent applications.
BioAtla Company Overview
BioAtla, based in San Diego, California, focuses on developing novel therapeutics that offer improved safety and efficacy for cancer treatment. The company leverages a revolutionary platform to create conditionally active therapeutics capable of activation or inactivation under specific physiological conditions. Operations extend internationally, with facilities in the Life Science Park in the Changping District of Beijing, China.
BioAtla Technological Platforms
BioAtla's primary technological platforms include Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™). CAB technology utilizes the unique diseased tissue microenvironment to target cancer more effectively, enabling the creation of antibodies or other biologics that are conditionally active. The CIAO!™ platform integrates essential manufacturing and process development features from the discovery phase of these proteins.
BioAtla Patents and Intellectual Property
BioAtla's innovative approach in the biotechnology sector is backed by extensive intellectual property. The company holds 713 patents, including 436 granted patents, 9 allowed patents, and 268 pending patent applications. These patents encompass various areas of their CAB technology and products.
BioAtla Therapeutic Pipeline
BioAtla has a robust pipeline of conditionally active biologic (CAB) therapeutics. Their CAB-ADCs aim to overcome current ADC limitations by targeting cancer cells more selectively. CAB-Bispecifics are engineered to bind to both tumor-specific antigens and T cell receptors. Additionally, BioAtla's CAB immune checkpoint inhibitors and stimulators are designed to target immune cells or tumor cells.
Collaborations and Partnerships
BioAtla collaborates with various partners to advance its technology and therapeutic offerings. Exuma Biotechnology is developing conditionally active Chimeric Antigen Receptor-T cell (CAR-T) therapies using BioAtla's CAB platform. In addition, Himalaya Therapeutics holds an exclusive license to develop and commercialize certain CAB candidates in the Greater China market. These collaborations enable BioAtla to expand the application of its CAB technology globally.